Regeneron Pharmaceuticals (REGN) 296.74 $REGN
SmarTrend Watching for Potential Pullback in Shares of Regeneron Pharmaceuticals After 4.19% Gain
Comtex SmarTrend(R) - Wed Apr 16, 5:15PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $291.75 to a high of $301.00. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $299.24 on volume of 955,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Will This Coverage Initiation Help Regeneron (REGN) Stock Today?
at The Street - Wed Apr 16, 7:43AM CDT
Regeneron Pharmaceuticals (REGN) had coverage initiated on its shares with a 'buy' rating by analysts at Canaccord Genuity
Anacor Pharma Remains Over-Valued on Development of Inferior Drugs
at The Street - Wed Apr 16, 7:00AM CDT
Investors have yet to fully bake in risks of Anacor's two lead drugs flopping commercially.
Good News for BioMarin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 6:05PM CDT
The FDA has extended Kuvan's marketing exclusivity period.
Bristol-Myers Seeks Approval for HIV Combo Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 5:30PM CDT
Bristol-Myers is looking to get the once-daily, single tablet fixed-dose combination approved in conjunction with other antiretroviral agents for the treatment of HIV-1 infection.
Repros Completes Enrollment for Androxal Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 5:15PM CDT
Repros Therapeutics announced it has completed enrollment for one of the two head-to-head studies on its secondary hypogonadism candidate, Androxal.
Encouraging Results from Lexicon Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 4:20PM CDT
Lexicon announced encouraging results from a phase II study on LX4211.
Health Care Stocks: Check Out This Low-Cost Market Beater
Selena Maranjian, The Motley Fool - Motley Fool - Tue Apr 15, 4:15PM CDT
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some health care stocks to your portfolio but don't have the time or expertise to hand-pick a few, the iShares US Healthcare ETF ...
FDA Nod for Merck's Grastek - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 4:11PM CDT
Merck announced that the FDA has approved Grastek, a timothy grass pollen allergen extract.
Portola's Betrixaban Study Design Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:30PM CDT
Portola announced the publication of the design and rationale of the phase III APEX study on betrixaban.
Another Earnings Beat from J&J, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 1:17PM CDT
J&J's earnings streak continues with the company reporting strong first quarter results and raising its guidance for the year.
Ambit Biosciences Slumps: AMBI Falls 13.0% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:40AM CDT
Ambit Biosciences falls 13% last trading session, continuing the downtrend
Why Is Regeneron Pharmaceuticals, Inc. Bucking the Downtrend?
George Budwell, The Motley Fool - Motley Fool - Mon Apr 14, 5:30PM CDT
Biotech stocks are awash in a sea of red for the most part right now. Turning to the gory details, 89% of biotechs finished in negative territory last week -- with the vast majority falling by double digits. Although this downturn is certainly...
Acquisitions, Director Appointments, Collaborations, New Product Launches, and Earnings Guidance Revisions - Analyst Notes on Questcor, Regeneron, Lilly, Medtronic and Alexion
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Eli Lilly and Co. (NYSE: LLY), Medtronic Inc. (NYSE: MDT) and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1084-100free.
The Cost to Treat Cholesterol Plummets, But Will It Last?
Todd Campbell, The Motley Fool - Motley Fool - Sun Apr 13, 9:00AM CDT
Every year, Express Scripts crunches the previous year's data to uncover payer spending trends. One of the most encouraging of those trends is the steep drop-off in spending on cholesterol-lowering drugs. Last year, health care payers forked over...
Regeneron to Report First Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on May 8, 2014
PR Newswire - Fri Apr 11, 8:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2014 financial and operating results on Thursday, May 8, 2014, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Clinical Trial Results and Initiation, Endowment, Product Launches, and Appointments - Analyst Notes on Regeneron, Questcor, Jazz, Ariad, and BioMarin
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Is the robust IPO market affecting the broader indices?
at The Street - Thu Apr 10, 2:53PM CDT
There has been a lot of debate of late about whether some of the pain in the so-called momentum names in the last month has something to do with growth money coming into the IPO space...
Technical Coverage on Top Gainers -- Research on Gogo, NQ Mobile, Regeneron Pharma, and American Superconductor
PR Newswire - Thu Apr 10, 12:30PM CDT
The US markets saw a positive sentiment on Wednesday, April 09, 2014, with the NASDAQ Composite closing at 4,183.90, up 1.72%, the Dow Jones Industrial Average ending the session at 16,437.18, up 1.11%, and the S&P 500 gained 1.09% to finish the trading session at 1,872.18. The gains were broad based as eight out of ten sectors finished on a positive note. A number of stocks saw large movements, including Gogo Inc. (NASDAQ: GOGO), NQ Mobile Inc. (NYSE: NQ), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) and American Superconductor Corp. (NASDAQ: AMSC). Free technical research on GOGO, NQ, REGN and AMSC can be downloaded upon signing up at:
Watch for Regeneron Pharmaceuticals to Potentially Pullback After Gaining 6.92% Yesterday
Comtex SmarTrend(R) - Wed Apr 09, 3:41PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $287.01 to a high of $306.96. Yesterday, the shares gained 6.9%, which took the trading range above the 3-day high of $301.84 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SmarTrend Watching for Potential Pullback in Shares of Regeneron Pharmaceuticals After 4.19% Gain
Comtex SmarTrend(R) - Wed Apr 16, 5:15PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $291.75 to a high of $301.00. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $299.24 on volume of 955,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Will This Coverage Initiation Help Regeneron (REGN) Stock Today?
at The Street - Wed Apr 16, 7:43AM CDT
Regeneron Pharmaceuticals (REGN) had coverage initiated on its shares with a 'buy' rating by analysts at Canaccord Genuity
Anacor Pharma Remains Over-Valued on Development of Inferior Drugs
at The Street - Wed Apr 16, 7:00AM CDT
Investors have yet to fully bake in risks of Anacor's two lead drugs flopping commercially.
Good News for BioMarin - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 6:05PM CDT
The FDA has extended Kuvan's marketing exclusivity period.
Bristol-Myers Seeks Approval for HIV Combo Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 5:30PM CDT
Bristol-Myers is looking to get the once-daily, single tablet fixed-dose combination approved in conjunction with other antiretroviral agents for the treatment of HIV-1 infection.
Repros Completes Enrollment for Androxal Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 5:15PM CDT
Repros Therapeutics announced it has completed enrollment for one of the two head-to-head studies on its secondary hypogonadism candidate, Androxal.
Encouraging Results from Lexicon Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 4:20PM CDT
Lexicon announced encouraging results from a phase II study on LX4211.
Health Care Stocks: Check Out This Low-Cost Market Beater
Selena Maranjian, The Motley Fool - Motley Fool - Tue Apr 15, 4:15PM CDT
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some health care stocks to your portfolio but don't have the time or expertise to hand-pick a few, the iShares US Healthcare ETF ...
FDA Nod for Merck's Grastek - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 4:11PM CDT
Merck announced that the FDA has approved Grastek, a timothy grass pollen allergen extract.
Portola's Betrixaban Study Design Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 3:30PM CDT
Portola announced the publication of the design and rationale of the phase III APEX study on betrixaban.
Another Earnings Beat from J&J, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 1:17PM CDT
J&J's earnings streak continues with the company reporting strong first quarter results and raising its guidance for the year.
Ambit Biosciences Slumps: AMBI Falls 13.0% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:40AM CDT
Ambit Biosciences falls 13% last trading session, continuing the downtrend
Why Is Regeneron Pharmaceuticals, Inc. Bucking the Downtrend?
George Budwell, The Motley Fool - Motley Fool - Mon Apr 14, 5:30PM CDT
Biotech stocks are awash in a sea of red for the most part right now. Turning to the gory details, 89% of biotechs finished in negative territory last week -- with the vast majority falling by double digits. Although this downturn is certainly...
Acquisitions, Director Appointments, Collaborations, New Product Launches, and Earnings Guidance Revisions - Analyst Notes on Questcor, Regeneron, Lilly, Medtronic and Alexion
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Eli Lilly and Co. (NYSE: LLY), Medtronic Inc. (NYSE: MDT) and Alexion Pharmaceuticals Inc. (NASDAQ: ALXN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1084-100free.
The Cost to Treat Cholesterol Plummets, But Will It Last?
Todd Campbell, The Motley Fool - Motley Fool - Sun Apr 13, 9:00AM CDT
Every year, Express Scripts crunches the previous year's data to uncover payer spending trends. One of the most encouraging of those trends is the steep drop-off in spending on cholesterol-lowering drugs. Last year, health care payers forked over...
Regeneron to Report First Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on May 8, 2014
PR Newswire - Fri Apr 11, 8:30AM CDT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2014 financial and operating results on Thursday, May 8, 2014, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Clinical Trial Results and Initiation, Endowment, Product Launches, and Appointments - Analyst Notes on Regeneron, Questcor, Jazz, Ariad, and BioMarin
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Is the robust IPO market affecting the broader indices?
at The Street - Thu Apr 10, 2:53PM CDT
There has been a lot of debate of late about whether some of the pain in the so-called momentum names in the last month has something to do with growth money coming into the IPO space...
Technical Coverage on Top Gainers -- Research on Gogo, NQ Mobile, Regeneron Pharma, and American Superconductor
PR Newswire - Thu Apr 10, 12:30PM CDT
The US markets saw a positive sentiment on Wednesday, April 09, 2014, with the NASDAQ Composite closing at 4,183.90, up 1.72%, the Dow Jones Industrial Average ending the session at 16,437.18, up 1.11%, and the S&P 500 gained 1.09% to finish the trading session at 1,872.18. The gains were broad based as eight out of ten sectors finished on a positive note. A number of stocks saw large movements, including Gogo Inc. (NASDAQ: GOGO), NQ Mobile Inc. (NYSE: NQ), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) and American Superconductor Corp. (NASDAQ: AMSC). Free technical research on GOGO, NQ, REGN and AMSC can be downloaded upon signing up at:
Watch for Regeneron Pharmaceuticals to Potentially Pullback After Gaining 6.92% Yesterday
Comtex SmarTrend(R) - Wed Apr 09, 3:41PM CDT
Regeneron Pharmaceuticals (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $287.01 to a high of $306.96. Yesterday, the shares gained 6.9%, which took the trading range above the 3-day high of $301.84 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
